Real-World study tests Once-Daily pill for diabetes control

NCT ID NCT04878393

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study followed 650 adults with type 2 diabetes in Japan who were already prescribed oral semaglutide (Rybelsus) by their doctors. Researchers tracked changes in blood sugar levels and body weight over 8-10 months, along with any side effects. The goal was to see how the medication performs outside of controlled clinical trials, in routine care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral semaglutide (Rybelsus)
What this could lead to: If successful, this could confirm that oral semaglutide effectively lowers blood sugar and helps with weight loss in everyday clinical practice for people with type 2 diabetes.
What could go wrong: This is an observational study without a comparison group, so results may be influenced by other factors. Side effects like nausea or diarrhea are possible with semaglutide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Show contact details

Locations

Master Centre for Japan

Tokyo, 1000005, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.